The objective of this study was to identify additional diabetes susceptibility markers in the MHC that could be responsible for the differential diabetogenicity of different HLA-DR3 CEHs. High-resolution SNP genotyping of the MHC was carried out in 15 type 1 diabetes (T1D) patients and 39 non-diabetic controls, homozygous for DR3-DQ2 and with one copy of the A*30-B*18-MICA*4-F1C30-DRB1*0301-DQB1*0201-DPB1*0202 HLA haplotype. Significantly associated SNPs were replicated in an independent sample of 554 T1D patients and 841 controls without HLA matching. Electrophoretic mobility shift assay was used to show a functional effect of an associated SNP. Seven SNPs showed evidence of association in the initial discovery experiment. Upon replication, only rs419434 (upstream HLA-DOA gene) remained significant. A functional variant (rs432375) in complete LD with rs419434 was shown to affect USF-1 binding and could be responsible for the association signal in the region. We have identified a new susceptibility locus within the MHC with a modest contribution to T1D (OR ¼ 1.93; CI: 1.52-2.44; P ¼ 10 À8 ) that is independent of HLA-DRB1 locus.
Introduction
The largest contribution to the genetic predisposition to type 1 diabetes (T1D) maps to the HLA class II region on the MHC, and a strong association of DR3-DQ2 and DR4-DQ8 haplotypes has been very consistently replicated across all Caucasian population groups. It is also widely accepted that the MHC could harbor additional loci that contribute to genetic susceptibility to the disease. [1] [2] [3] However, the high degree of linkage disequilibrium (LD) within this region has made it difficult to demonstrate that such association signals are truly independent of HLA-DR/DQ risk. In fact, long genomic extensions, termed conserved extended haplotypes (CEHs), or ancestral haplotypes that have been maintained unaltered during human evolution, are characteristic of this genomic region. 4 A particular HLA-DR3 CEH (A*30-B*18-MICA*4-F1C30-DRB1*0301-DQB1*0201-DPB1 *0202, or B18-DR3) that is relatively common in southern European populations has been shown to be conserved across a 5-Mb region and to be more diabetogenic than other HLA-DR3 chromosomes. 5, 6 These findings support the hypothesis that B18-DR3 chromosomes carry additional risk alleles in other susceptibility loci, which are fixed in all B18-DR3 CEHs, but may not be always present in other less-predisposing DR3 chromosomes. Under this hypothesis and in order to search for possible additional T1D susceptibility loci, we have carried out high-resolution SNP genotyping of the MHC region, comparing HLA-DR3 homozygous T1D patients and non-diabetic individuals carrying one copy of the B18-DR3 CEH, so that we can investigate putatively diabetogenic variation at the other HLA-DR3 chromosome. We report evidence for association of a marker close to HLA-DOA gene located at 33.08 Mb that seems to be independent of HLA-DR/DQ, and propose a functional polymorphism at a TFBS as the possible etiological variation underlying this association peak.
Results and discussion
Although during the past years a great amount of effort has been put to the search of additional T1D susceptibility loci in the MHC, results so far have been somewhat controversial. [7] [8] [9] [10] The discrepancies found among studies could reflect the existence of multiple and unevenly distributed disease-predisposing variants, and could also be partly explained by the extreme complexity of the region. ) ( Figure 1 ) (Online Appendix, Table 1 ), and genotypes were confirmed using Taqman assays. Three of the associated SNPs were located telomeric to HLA-B locus at 31.42 Mb, in a region spanning 1.5 Mb. The most telomeric SNP, rs10946990 (29 504 625), is located upstream of OR11A1 gene at 29.50 Mb, outside the classical MHC. The other two SNPs in the region, rs2284165 (30 268 034) and rs2844650 (31 010 512), are located, respectively, in an intron of TRIM26 at 30.26 Mb and upstream of SFTPG at 31.00 Mb. There are several reports describing associations around this extended region, including the region near HLA-A (30.01 Mb) or HLA-B, 7 and also in the extended MHC region close to UBD (0.98 Mb) and MASL1 (0.87 Mb) genes. 8 The remaining four associated SNPs in our study are located centromeric to the classical T1D loci (HLA-DR/DQ), in a region extending from 33 091 452 to 33 243 940, between HLA-DOA and COL11A2 (33.24 Mb). In this centromeric region, ITPR3 (33.69 Mb) was initially proposed as a susceptibility gene, 10 although this association was later revoked because of LD with HLA-DRB1 risk alleles. 7, 13 In order to confirm the association of these seven SNPs with the disease, six of them were genotyped in a larger, independent sample set without HLA-matching. As rs419434 and rs423209 are in total LD with an r 2 ¼ 1 (both in our population and in the Hapmap CEU data), only rs419434 was genotyped to represent both SNPs. rs419434 was the only SNP for which association with T1D was replicated (P ¼ 1 Â 10 À8 ; OR (95% CI) ¼ 1.93 (1.52-2.44)) ( Table 1 ). This SNP is upstream of HLA-DOA, an HLA class II a chain paralog expressed in B cells and involved in the regulation of HLA-DM-mediated peptide loading on MHC class II molecules. HLA-DOA is located approximately 0.5 Mb centromeric from HLA-DRB1, so two tag SNPs, rs2187668 and rs7454108, that are proxies for HLA-DR3/DQ2 and HLA-DR4/DQ8, respectively, 14, 15 were genotyped and the LD between each of them and rs419434 was measured using Haploview (http://www.broad.mit.edu/mpg/haploview/). 16 No evidence for LD between rs419434 and HLA-DR3/DQ2 or with HLA-DR4/DQ8 was observed (r 2 o0.1), and haplotype-based association analyses of rs419434 risk allele after stratication for the effects of DR3 and DR4 also supported independent contribution of rs419434 to T1D (Table 2) .
Although it is generally accepted that the degree of LD throughout the MHC is relatively constant until it drops centromeric to HLA-DPB1, there is evidence showing that it fluctuates greatly among MHC subregions and is particularly lower in the classical HLA class II and extended class II regions, where several recombination hotspots have been identified. 17, 18 In particular, HLA- 6 all of them homozygous for DR3-DQ2 and carrying only one copy of the A*30-B*18-MICA*4-F1C30-DRB1*0301-DQB1*0201-DPB1*0202 (B18-DR3) CEH. Overlapping SNPs with more than two discrepant calls between panels, those with minor allele frequency o0.01 and those failing HWE test (Po0.001) in cases or in controls were eliminated before disease-association analyses. All downstream analyses were carried out using the PLINK v2.044 association analysis tool set (http:// pngu.mgh.hravard.edu/~purcell/plink/). 12 Fisher's exact test was used for single-marker allelic association analysis, and P-values below 10 À3 were regarded significant.
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DOA is flanked by two such recombination hotspots, close to Bromodomain-containing 2 (BRD2) on the telomeric side and to HLA-DPA1 on the centromeric side 19, 20 (Online Appendix, Figure 1 ). In an attempt to locate a functional variant that could explain this association signal, we searched within the region of 59 kb between these two recombination hotspots for SNPs in total correlation with rs419434 (r 2 ¼ 1) that were predicted in silico to be regulatory SNPs. Out of the four SNPs that were perfect proxies for rs419434 according to the HapMap CEU data (http://www.hapmap.org), rs432375, which had not been genotyped in our discovery data set, was predicted to disrupt a binding site for upstream stimulatory factor 1 (USF-1) with a match score 498.0, based on FastSNP (http:// fastsnp.ibms.sinica.edu.tw) and MatInspector v.7.7.3 demonstration version (http://www.genomatix.de/products/MatInspector/MatInspector2.html) results. To confirm this theoretical effect, we carried out a functional analysis using an electrophoretic mobility shift assay (EMSA) and observed that the minor allele (allele C) provoked a moderate decrease in the binding capacity of USF-1, which was more pronounced at lower protein concentrations (Figure 2 ). This alteration of binding affinity could possibly affect the level, timing and localization of the gene product, which could in turn have an effect on disease pathogenesis. For instance, SNPs in intronic or intergenic regulatory sequences that are binding sites for transcription factor RUNX1 have been associated with different autoimmune diseases, including systemic lupus erythematosus 21 and rheumatoid arthritis. 22 We subsequently genotyped rs432375 in our sample set using a custom Taqman Allelic Discrimination Assay (Applied Biosystems, Foster City, CA, USA), designed using Primer Express V3.0 software (Applied Biosystems). Owing to the complexity of the region, allele-specific probes were designed with a degenerate base (Online Appendix). Our results showed that this SNP was not in total LD with rs419434 (r 2 ¼ 0.92) in our population, but was still significantly associated with the disease (P ¼ 3 Â 10
À7
; OR (95% CI) ¼ 1.78 (1.42-2.25)). The presence of another SNP (rs11935463) only two bases away from rs432375 complicated the genotyping assay design, making it necessary to include four oligonucleotide probes in the assay mix, and might influence the performance of the Taqman assay. Although samples were genotyped in duplicate and only concordant replicates were included in the association analysis, results are less robust than those obtained for rs419434, and the few inconsistencies observed between the two associated SNPs could be due in part to genotyping errors unsolvable with this methodology.
In this study, we present the association with T1D of a marker close to HLA-DOA that seems to be independent of HLA class II-conferred risk. Further studies in other populations will clarify whether this polymorphism is associated with T1D in different populations or restricted to southern European populations. We also propose a functional variant that provokes a subtle alteration in the binding of transcription factor USF-1 as the underlying Table 1 Results of the replication study of the most significantly associated SNPs, carried out in an HLA-unmatched, independent sample set comprising 554 T1D patients and 841 healthy white blood donors of southern European origin, using pre-designed Taqman SNP Genotyping Assays (Applied Biosystems) Diabetogenicity of the HLA-B18-DR3 CEH I Santin et al etiological culprit, but again, further analyses are necessary to confirm whether this disruption has an effect on gene expression in vivo, of HLA-DOA (cis effect) or other genes (trans effect). An attractive hypothesis would link a defect in HLA-DOA regulatory elements with an enhanced cellular immune response, based on data suggesting that overexpression of HLA-DOA correlates with a reduction in antigen presentation to T cells. 23 This exciting idea needs experimental confirmation before it can be accepted. Finally, we have successfully employed a CEH-matching strategy to control for the major effects of HLA loci and to detect modest contribution to T1D risk. Our growing knowledge of the MHC structure will make similar approaches with other CEH possible, in order to investigate whether other minor T1D-susceptibility loci are present in the MHC.
